Teva Pharmaceutical Prices Upsized $2.3 Billion Notes Offering

MT Newswires Live

05/21

Teva Pharmaceutical Industries (TEVA) said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.

The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros ($1.13 billion) aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.

Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537462615"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537462615\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537462615?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537462615","market":"sh","top_or_hot":-1,"title":"Teva Pharmaceutical Prices Upsized $2.3 Billion Notes Offering","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical Industries (TEVA) said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.</p><p>The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros ($1.13 billion) aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.</p><p>Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Prices Upsized $2.3 Billion Notes Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Prices Upsized $2.3 Billion Notes Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-21 05:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Teva Pharmaceutical Industries (TEVA) said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.</p><p>The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros ($1.13 billion) aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.</p><p>Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2537462615","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537462615","pubTimestamp":1747777399,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries  said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros  aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4584":"避孕概念","BK4566":"资本集团","BK4007":"制药","TEVA":"梯瓦制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4557":"大麻股"},"translate_title":"梯瓦制药价格上调23亿美元票据发行规模","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries (TEVA) said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros ($1.13 billion) aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}